Arteriocyte, Inc.

Company Information
Address 7100 Euclid Ave Ste 150
Cleveland, OH, 44103-4043


Information

DUNS: 191821342

# of Employees: N/A


Ownership Information

Hubzone Owned: N

Socially and Economically Disadvantaged: N

Woman Owned: N



Award Charts




Award Listing

  1. SMART Bandage for Monitoring Wound Perfusion

    Amount: $69,048.00

    ABSTRACT: Arteriocyte intends to develop and commercialize an innovative wound dressing. This SMART Bandage will incorporate an optical oxygen sensor and provide oxygen measurements of underlying wou ...

    SBIRPhase I2014Department of Defense Air Force
  2. Hematopoietic Reconstitution Using Ex Vivo Expanded Cord Blood CD34+ Cells

    Amount: $283,861.00

    DESCRIPTION (provided by applicant): Umbilical cord blood (UCB) provides unique advantages over bone marrow (BM) and mobilized peripheral blood (MPB) as a source of hematopoietic stem cells (HSCs) for ...

    SBIRPhase I2012Department of Health and Human Services
  3. RAPID, HIGH VOLUME PRODUCTION OF RETICULOCYTES FOR P. VIVAX MALARIA RESEARCH

    Amount: $219,995.00

    DESCRIPTION (provided by applicant): Malaria results from infection by one of five species of mosquito-borne parasite. Each year, these protists infect 350-500 million worldwide and kill over one mill ...

    SBIRPhase I2011Department of Health and Human Services
  4. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    Amount: $2,196,210.00

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pa ...

    SBIRPhase II2010Department of Health and Human Services
  5. A Novel Expansion of Primary Leukemia Stem Cells

    Amount: $304,943.00

    DESCRIPTION (provided by applicant): Arteriocyte's long-term objective is to develop a platform for ex vivo expansion of leukemic stem cell (LSC) based on cytokine-enriched medium and the company's pr ...

    SBIRPhase I2010Department of Health and Human Services
  6. Therapeutic Potential of Ex vivo expanded Human Cord Blood derived CD133+ cells i

    Amount: $281,794.00

    DESCRIPTION (provided by applicant): Critical Limb Ischemia (CLI) is a common problem that often results in major limb amputation. Circulating endothelial progenitor cells likely play a role in the pa ...

    SBIRPhase I2008Department of Health and Human Services
  7. CAN CD 133 CELLS PREVENT HYPOXIA DRIVEN RETINAL NEOVASCULARISATION IN A RODENT MO

    Amount: $310,645.00

    DESCRIPTION (provided by applicant): The clinical significance of ocular angiogenesis is enormous, due to the fact that in the western hemisphere, retinal neovascularization resulting from diabetic re ...

    STTRPhase I2007Department of Health and Human Services
  8. Marrow-Derived Stem Cells for Coronary Artery Ischemia

    Amount: $1,229,607.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective ...

    STTRPhase II2006Department of Health and Human Services
  9. Marrow-Derived Stem Cells for Coronary Artery Ischemia

    Amount: $142,954.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective ...

    STTRPhase I2005Department of Health and Human Services
  10. Marrow-Derived Stem Cells for Coronary Artery Ischemia

    Amount: $142,954.00

    DESCRIPTION (provided by applicant): Cardiovascular disease is the leading cause of morbidity and mortality in the United States, accounting for approximately 1 million deaths per year. The objective ...

    SBIRPhase IDepartment of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government